Trial sponsor China
Neurophth Therapeutics
Wuhan Neurophth Biotechnology
China-based biotech running the most advanced commercial LHON gene therapy program. GOLD trial (NCT04912843, Phase 1/2/3) and bilateral IVT Phase 3 (NCT07406854) target ND4 mutations. Also pursued NFS-02 for ND1 (NCT05820152, terminated 2024).
Research focus
NR082 gene therapyNFS-02commercial LHON therapeutics
Public profiles
- Website: https://www.neurophth.com/
Contact is made via official institutional channels, not private email. To request removal, email the project.
Relevant project findings
Neurophth is the most commercially advanced LHON gene therapy sponsor globally, with two active Phase 3 trials for NR082. Their competitive landscape against GenSight’s LUMEVOQ makes them a key stakeholder for trial sponsor outreach.
Project outreach status
Not yet contacted